194,026 Shares in Natera, Inc. $NTRA Purchased by AustralianSuper Pty Ltd

AustralianSuper Pty Ltd bought a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the second quarter, according to the company in its most recent filing with the SEC. The firm bought 194,026 shares of the medical research company’s stock, valued at approximately $32,779,000. AustralianSuper Pty Ltd owned approximately 0.14% of Natera as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Natera by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 12,393,827 shares of the medical research company’s stock valued at $1,752,611,000 after acquiring an additional 77,357 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in Natera by 56.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 10,537,743 shares of the medical research company’s stock valued at $1,490,144,000 after acquiring an additional 3,795,315 shares in the last quarter. JPMorgan Chase & Co. increased its position in Natera by 9.9% in the 1st quarter. JPMorgan Chase & Co. now owns 7,361,963 shares of the medical research company’s stock valued at $1,041,055,000 after acquiring an additional 660,538 shares in the last quarter. Invesco Ltd. increased its position in Natera by 13.7% in the 1st quarter. Invesco Ltd. now owns 2,035,979 shares of the medical research company’s stock valued at $287,908,000 after acquiring an additional 245,719 shares in the last quarter. Finally, Maverick Capital Ltd. increased its position in Natera by 19.7% in the 1st quarter. Maverick Capital Ltd. now owns 1,634,769 shares of the medical research company’s stock valued at $231,173,000 after acquiring an additional 268,715 shares in the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Price Performance

Natera stock opened at $192.22 on Tuesday. The company’s 50 day simple moving average is $171.92 and its 200 day simple moving average is $160.71. Natera, Inc. has a fifty-two week low of $117.27 and a fifty-two week high of $198.99. The firm has a market capitalization of $26.38 billion, a price-to-earnings ratio of -100.64 and a beta of 1.74.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.14). Natera had a negative return on equity of 22.22% and a negative net margin of 12.89%.The firm had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same period in the previous year, the business earned ($0.30) EPS. The firm’s revenue was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. As a group, analysts predict that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Insider Buying and Selling at Natera

In related news, Director Rowan E. Chapman sold 2,750 shares of Natera stock in a transaction that occurred on Thursday, August 28th. The shares were sold at an average price of $166.99, for a total transaction of $459,222.50. Following the transaction, the director owned 6,015 shares of the company’s stock, valued at $1,004,444.85. This trade represents a 31.37% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Gail Boxer Marcus sold 2,496 shares of Natera stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $133.17, for a total transaction of $332,392.32. Following the transaction, the director directly owned 5,763 shares in the company, valued at $767,458.71. The trade was a 30.22% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,374 shares of company stock worth $9,108,022 over the last ninety days. 5.63% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

NTRA has been the subject of several research reports. Zacks Research cut shares of Natera from a “hold” rating to a “strong sell” rating in a research report on Monday, October 20th. BNP Paribas raised shares of Natera to a “neutral” rating and set a $172.00 target price on the stock in a research note on Monday. BTIG Research raised their target price on shares of Natera from $200.00 to $210.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Wells Fargo & Company started coverage on shares of Natera in a research note on Monday, September 22nd. They issued an “equal weight” rating and a $175.00 target price on the stock. Finally, Morgan Stanley reaffirmed an “overweight” rating and issued a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $194.89.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.